Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer
Gillian Vandekerkhove(University of British Columbia), Alexander W. Wyatt(University of British Columbia), Alan So(University of British Columbia), Teuvo L.J. Tammela(Tampere University), Yulia Loktionova(University of British Columbia), Ladan Fazli, Heini Kallio(Tampere University), Daniel Khalaf(BC Cancer Agency), Matti Annala(Tampere University), Peter C. Black(University of British Columbia), Martin Gleave(University of British Columbia), Matti Nykter(University of Liverpool), Werner J. Struss(University of British Columbia), Cameron Herberts(Natera (United States)), Elie Ritch(University of British Columbia), Antonio Hurtado‐Coll(University of British Columbia), Kim N.(Asian Institute of Technology), Evan W. Warner(Guardant (United States)), Kevin Beja(University of British Columbia)
Cited by 183
Related Papers
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2012|1.4k